The long-awaited US approval of its newest artificial pancreas comes through, but Medtronic remains behind.
The group is fast developing its new atrial fibrillation devices. But will it be fast enough?
Being first does not always mean a clear win.
The purchase of Nuvasive for $3.1bn is the biggest ortho deal for some time – and integration will be tough.
Device approvals hit a nine-year low in 2022, as the FDA takes its foot further off the gas.
J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.